Endoron Medical
Endoron is developing a catheter-based endograft stapling solution to overcome the challenges associated with the sealing and fixation of endografts used for the minimally invasive repair of abdominal aortic aneurysms.
The EndoStapling solution, designed to avoid highly invasive, high-mortality open surgery, is meant to secure an endograft's fixation and to improve sealing mechanisms. About 400,000 new patients in the U.S. and Europe are diagnosed with AAA disease every year, with 42% presenting complex anatomies.
Founded in 2019, Endoron Medical builds on an invention from Prof. Ron Karmeli (Hadassah Hospital, Jerusalem), who is co-founder and Chief Medical Officer of the Company.
Cécile Dupont, Senior Associate and Program Director at Sofinnova Partners MS Start III Fund, is joining the Endoron management team to bring greater operational and strategic support.
Sector
Medical Devices
Strategy
MD Start
Status
Live
Website
endoronmedical.com
Related News
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.